Displaying drugs 551 - 575 of 8039 in total
Gamolenic acid
Gamolenic acid, or gamma-linolenic acid (γ-Linolenic acid) or GLA, is an essential fatty acid (EFA) comprised of 18 carbon atoms with three double bonds that is most commonly found in human milk and other botanical sources . It is an omega-6 polyunsaturated fatty acid (PUFA) also referred to as 18:3n-6;...
Approved
Investigational
Matched Description: … ] and [DB11238] are rich sources of gamolenic acid. ... acid, or gamma-linolenic acid (γ-Linolenic acid) or GLA, is an essential fatty acid (EFA) comprised of ... It is converted to [DB00154], a biosynthetic precursor of monoenoic prostaglandins such as PGE1. …
Fenofibric acid
Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.[A32038,L12855] Due to its high hydrophilicity and poor absorption profile, prodrug ,fenofibrate, and other conjugated compounds...
Approved
Matched Description: … hydrophilicity and poor absorption profile,[A32038] prodrug ,[fenofibrate], and other conjugated compounds of …
Ivosidenib
Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA...
Approved
Investigational
Matched Description: … relapsed of refractory acute myeloid leukemia in adults. ... [A248745]
Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of ... A248750] Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of …
Remdesivir
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase...
Approved
Investigational
Matched Description: … [A191379, A222393] Broad antiviral activity of remdesivir is suggested by its mechanism of action,[A222398 ... Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease ... 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and …
Minoxidil
A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure.
Approved
Investigational
Nabumetone
Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a degree...
Approved
Matched Description: … [label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate ... [A179077] While slightly reduced, possibly due to a degree of cyclooxygenase-2 selectivity (COX-2), nabumetone …
Nabilone
Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as...
Approved
Investigational
Matched Description: … , a class of compounds that act upon endogenous cannabinoid receptors of the body [A32584]. ... psychoactive component of cannabis (marijuana). ... Nabilone is a racemate consisting of the (S,S) and the (R,R) isomers. …
Bromocriptine
Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as the treatment of acromegaly. Bromocriptine has been...
Approved
Investigational
Withdrawn
Matched Description: … Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as ... In 1995, the FDA withdrew the approval of bromocriptine mesylate for the prevention of physiological ... well as the treatment of acromegaly. …
Enprofylline
Enprofylline is a derivative of theophylline which shares bronchodilator properties. Enprofylline is used in asthma, chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy. Long-term enprofylline administration may be associated with elevation in liver enzyme levels and unpredictable blood levels.
Approved
Experimental
Matched Description: … Enprofylline is a derivative of theophylline which shares bronchodilator properties. ... Enprofylline is used in asthma, chronic obstructive pulmonary disease, and in the management of cerebrovascular …
Celiprolol
Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris. It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 receptor antagonist. In 2010 a clinical trial has suggested a use for this medication in the prevention of...
Approved
Investigational
Matched Description: … rupture in which the layers of the vessel separate prior to complete failure of the artery wall). ... This study demonstrated decreased incidence of arterial rupture or dissection (a specific type of arterial ... of a rare inherited disease called vascular Ehlers–Danlos syndrome. …
Pramipexole
Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a non-ergot dopamine agonist drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement) . It was first approved by the FDA in 1997 . Parkinson's Disease is...
Approved
Investigational
Matched Description: … Parkinson's Disease is one of the most common neurodegenerative disorders and causes a high level of ... Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). ... The prevalence of Parkinson's Disease worldwide has increased from approximately 2.5 million in 1990 …
Insulin aspart
Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the...
Approved
Matched Description: … high levels of insulin in a short period of time to mimic the release of endogenous insulin from the ... , with a goal of avoiding any periods of hypoglycemia. ... Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type …
Lorazepam
Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.
Approved
Crizanlizumab
Crizanlizumab is a humanized IgG2 monoclonal antibody used to reduce the frequency of vaso-occlusive crises in patients with sickle cell disease. Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and certain parts of India. The genetic mutation associated with this disease leads to the...
Approved
Investigational
Matched Description: … of reducing morbidity and mortality. ... Crizanlizumab is a humanized IgG2 monoclonal antibody used to reduce the frequency of vaso-occlusive ... disease is a genetically inherited condition prevalent in the Middle East, Africa, and certain parts of …
Clocortolone
Clocortolone is a medium potency corticosteroid that is often used as a topical cream for the relief of inflammatory oand pruritic (itching) arising from steroid-responsive dermatoses of the scalp.
Approved
Matched Description: … inflammatory oand pruritic (itching) arising from steroid-responsive dermatoses of the scalp. ... Clocortolone is a medium potency corticosteroid that is often used as a topical cream for the relief of …
Plicamycin
Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000.
Approved
Investigational
Withdrawn
Matched Description: … of hypercalcemia. ... It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management …
Bisoxatin
Bisoxatin is a stimulant laxative which increases peristalsis and inhibits absorbtion of water and ions in the intestine . It is marketed in Belgium under the tradename Wylaxine and used for the treatment of constipation and for preparation of the colon for surgical procedures.
Approved
Matched Description: … for preparation of the colon for surgical procedures. ... Bisoxatin is a stimulant laxative which increases peristalsis and inhibits absorbtion of water and ions ... It is marketed in Belgium under the tradename Wylaxine and used for the treatment of constipation and …
Adalimumab
Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor.[A39984,A39999] It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced...
Approved
Experimental
Matched Description: … Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid ... [L49101] A biosimilar marketed as Hyrimoz, a high-concentration formulation of adalimumab, is also available …
Sulconazole
Sulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream and solution. Sulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common pathogenic dermatophytes, making it an effective treatment for tinea cruris and tinea corporis infections.[L44592,L44597] Sulconazole appears to be effective...
Approved
Matched Description: … Sulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common ... [L44592,L44597] Sulconazole appears to be effective and well-tolerated in the treatment of superficial …
Cilgavimab
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … [A243351, A243356, L39411] As the RBD binding site of cilgavimab does not overlap with that of [tixagevimab ... reduce viral load and improve clinical symptoms of infection. ... The FDA and Health Canada advise healthcare providers to inform patients of this risk. …
Tixagevimab
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … [A243351, A243356, L39411] As the RBD binding site of tixagevimab does not overlap with that of [cilgavimab ... reduce viral load and improve clinical symptoms of infection. ... The FDA and Health Canada advise healthcare providers to inform patients of this risk. …
Melphalan flufenamide
Melphalan flufenamide, also known as melflufen or J1, is a prodrug of melphalan.[A230123,L32173] Melphalan flufenamide is more readily uptaken by cells than melphalan, and is cleaved to the active metabolite by aminopeptidases. In vitro models show that melphalan is 10 to hundreds of times more potent than melphalan. The increased...
Approved
Withdrawn
Matched Description: … Melphalan flufenamide, also known as melflufen or J1, is a prodrug of [melphalan]. ... [A230123] _In vitro_ models show that melphalan is 10 to hundreds of times more potent than melphalan ... option for patients with relapsed or refractory multiple myeloma who have attempted at least 4 lines of …
Tenecteplase
Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids...
Approved
Matched Description: … It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine ... Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA …
Albendazole
A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38)
Approved
Vet approved
Displaying drugs 551 - 575 of 8039 in total